Metformin is a drug that is given to the Diabetes type 2 condition. This drug works by targeting the AMP activated protein kinase (AMPK). This makes the muscles use the glucose in the body. Recent research has indicated that AMPK enzyme is used to regulate the protein kinase LKB1. This is a tumor suppressor. Hence, the purpose of this research was to show the use of Metformin for the Diabetes patients in reducing the risk of developing cancer. Using this factor as the background, there was research undertaken to understand the impact of Metformin apart from its use in controlling of the type 2 Diabetes condition.
A pilot case controlled study was tested with the database Tayside. The database was titled diabetes clinical information system. A random study was tested on the diabetic patients in the database. All the participants had diabetes 2 condition, some of the people in the study had developed cancer while the others did not have any evidence of cancer.
A cohort study was undertaken for this testing. A cohort study is a group of people with similar characteristics. In this case, it was the patients who had developed Diabetes. There were the test cases and the controls used for this research. Conditional logistic regression was done for this research. Condition logistic regression is used in the case-control study. The participant with one condition is matched with a study participant without the condition. In this case, the participants were all diabetes patients of which one group had cancer and the other group did not have cancer. However, there was the third controlled group to verify the impact of the drug. Since this was a cohort study, the metformin administration of the patients from 1993 was considered.
The results indicated that there was no real conclusive evidence that the administration of the drug had caused the prevention or reduced the impact of cancer progression. More participants were needed to understand the impact of the drug.
Since it has been proven that protein kinase LKB1 can be controlled by Metformin drug, the potential of the drug to handle the condition of cancer is established. However, it was concluded in this research that there should be more analysis and pathophysiological cycles analyzed in determining the efficacy of the drug. Future research will be directed towards developing this drug for the treatment of cancer.